These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
Dec 16, 2013
Agenus Inc. (Nasdaq: AGEN), a biotechnology company developing novel immune system activating treatments for cancers and infectious diseases, today announced results published from a Phase 2 study...
Nov 18, 2013Agenus’ Brain Cancer Vaccine Program Named a "Top Project to Watch" by Elsevier Business IntelligenceAgenus to present at 2013 Therapeutic Area Partnerships Conference
Agenus Inc. (Nasdaq: AGEN), a developer of therapeutic vaccines for cancer and infectious diseases, today announced that its Prophage Series (HSPPC-96) vaccine program for the treatment of brain...
Nov 7, 2013Agenus’ HerpV Therapeutic Vaccine for Genital Herpes Meets Primary Endpoint in Randomized Phase 2 TrialSUBJECTS TREATED WITH THE INITIAL THREE INJECTIONS OF HERPV SHOWED A STATISTICALLY SIGNIFICANT REDUCTION IN VIRAL SHEDDING, THE PRIMARY ENDPOINT
Agenus Inc. (Nasdaq: AGEN), a developer of therapeutic vaccines for cancer and infectious diseases, today announced statistically significant top-line results from its Phase 2 randomized,...
Oct 24, 2013Agenus to host conference call beginning at 11 a.m. ET today
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (NASDAQ: AGEN), a biotechnology company working to develop novel immunology based treatments for cancers and infectious diseases, today announced its...
Oct 16, 2013Agenus to Report Third Quarter 2013 Financial Results on October 24, 2013; Conference Call to Follow
Agenus Inc. (NASDAQ: AGEN) will release its third quarter 2013 financial results before the market opens on October 24, 2013. Agenus executives will host a conference call at 11:00 a.m. Eastern...